Open Access

The landscape of 8q24 cytoband in gastric cancer (Review)

  • Authors:
    • Violeta Larios-Serrato
    • Hilda-Alicia Valdez-Salazar
    • Martha-Eugenia Ruiz-Tachiquín
  • View Affiliations

  • Published online on: February 28, 2024     https://doi.org/10.3892/ol.2024.14311
  • Article Number: 179
  • Copyright: © Larios-Serrato et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Worldwide, gastric cancer (GC) is estimated to be the fifth most common type of cancer type in both sexes, ranking sixth for new cases, with >640,850 cases per year, and fourth in terms of mortality rate. Cancer presents numerical and structural alterations in chromosomes, often through gains and losses of regions. In GC, there are multiple genetic alterations, in which those located in cytoband 8q24 have been frequently described; essential genes are present in this cytoband, regulating the homeostasis of crucial biological processes, such as the MYC gene, which induces expression of selective genes to promote cell growth and proliferation. Conversely, DNA sequence variations can also occur when a single nucleotide in the genome sequence is altered, and this is termed a single nucleotide polymorphism (SNP). These alterations, which can serve as a biological marker, are present in at least 1% of the population and assist in identifying genes associated with GC. In the present review, 12 genes present in cytoband 8q24 related to GC (NSMCE2, PCAT1, CASC19, CASC8, CCAT2, PRNCR1, POU5F1B, PSCA, JRK, MYC, PVT1 and PTK2) are discussed. The PSCA gene was cited more frequently than others; it has four known SNPs associated with GC (rs2978980, rs2294008, rs2976392 and rs9297976). Thus, these SNPs should be further studied in different populations to determine their risk value in patients with GC.

Gastric cancer (GC)

Cancer is a group of genetic diseases characterized by the uncontrolled proliferation of heterogeneous cell populations with the ability to invade tissues locally and remotely from the site of origin (metastasis), responding to stimuli from the adjacent microenvironment and from the host organism. During oncogenesis, cancer not only escapes the host regulatory mechanisms, but also gains the ability to affect local and systemic homeostasis (1).

Cancer is the second leading cause of death worldwide; in 2022, 9,743,832 deaths were attributed to this disease, and it is estimated that the number of prevalent cases in 5 years will be 53,504,187 (2). Worldwide, GC is estimated to be the fifth most common cancer type in both sexes, ranking sixth for new cases, with 640,850 cases per year, and fourth in terms of mortality rate (GloboCan, 2020) (3).

The etiology of GC is complex, primarily due to genetic alterations and a set of factors (diet, lifestyle, genetics and socioeconomic factors). Significantly, 80% of cases are associated with infection with Helicobacter pylori (4,5).

Of note, <3% of GC cases are attributed to heredity causes, and these types of GC cancer cases include Hereditary GC (HGC), proximal polyposis of the stomach, and hereditary non-polyposis colorectal cancer (5). HGC is the best-known familial GC and is characterized by the loss of the CDH1 gene. Hereditary Diffuse GC (HDGC) is rare, with an incidence rate ranging from 0.3–3.1% in Korea and Japan. However, excluding the small portion of cases of familial GC syndrome, the risk of GC in those with a family history is three times higher vs. those with no history, which is higher than that for other adult solid cancer cases except ovarian cancer (6). Although family history is a systematically reported risk factor in GC, the molecular basis for familial clustering is unclear. Family members have shared exposure to carcinogens, (such as cigarette smoke and alcohol consumption), along with similar levels of hygiene, dietary habits (salty, spicy, and smoked foods), bacterial virulence, including Helicobacter pylori CagA+ and also genetic susceptibility (7).

Invasive GC is preceded by a long precancerous period, which can last for decades and thus provides ample opportunities to detect and treat precancerous lesions. When these lesions progress to an advanced stage, periodic endoscopic follow-ups should be performed to identify the lesions before they become invasive (8,9). Anatomic demarcations, histological differences, or both can be used to distinguish benign lesions from invasive lesions. Most relevant is the distinction between adenocarcinomas that arise from the cardia (the part of the stomach closest to the esophagus, cardia-GC) and other parts of the stomach (non-cardia-GC) (10). Currently, there are different histological classifications of GC, the most commonly used are the Lauren (11), Nakamura et al (12), Ming (8), Goseki et al (13), and the World Health Organization (WHO) classification systems (14).

GC can be divided into diffuse and intestinal GC based on its histological appearance as well as cardia and non-cardia-GC according to location. The epidemiological and molecular characteristics of GC differ according to the histological type and location of the tumor (6).

Intestinal-type GC (IGC) has well-defined structures or ductal chords surrounded by a zone of desmoplastic stroma. It forms adhesions or fibrous joint tissue within the tumor, with mixed inflammatory infiltration (15). IGC is observed more frequently in older adult patients and follows Correa's precancerous chain, which includes the following states: Atrophic gastritis, intestinal metaplasia and dysplasia (16). Tumor cells often have nuclei that are polymorphic and isochromatic with a coarse chromatin pattern; mitotic figures are thus easily detected. Intestinal-type carcinomas must be well or moderately differentiated, and diffuse-type adenocarcinomas have solitary or small groups of tumor cells without forming glandular structures (15).

Furthermore, Diffuse-type GC (DGC) occurs more frequently in younger patients, and there are no associations with atrophic gastritis or intestinal metaplasia (16). Clear cytoplasmic vacuoles may sometimes be observed. These cells that contain mucus push the nucleus to the periphery of the cell (signet ring cell carcinoma). The stroma formed is usually extensive, making it difficult to identify separate tumor cells on standard hematoxylin and eosin stains; additional keratin staining reveals the true extent of the tumor (15).

The pathogenicity of IGC has been well characterized and studied. However, diffuse GC (DGC) remains undefined, is considered genetically determined, and is less associated with environmental factors and the inflammatory cascade. Additionally, a minor proportion of DGC cases (1–3%) are inherently linked and associated with germline alterations in cell physiology, known as HDGC (7).

The stages of the precancerous cascade illustrated in Fig. 1 have been well characterized from the histopathological point of view. It is postulated that the progression from one stage to the next is determined by etiological factors linked to the inflammatory process and decades of progression (9). The stages of the precancerous cascade are non-atrophic gastritis, multifocal atrophic gastritis, complete intestinal metaplasia, incomplete intestinal metaplasia, dysplasia and adenocarcinoma (9).

Among the molecular pathogenesis, chromosome instability is involved (aneuploid, translocation, amplification, deletions and loss of heterozygosity), fusion genes, microsatellites instability (hypermethylation of promoters of DNA repair genes) and changes in gene expression profile (4,5,17).

Chromosomes and copy number alterations (CNA)

In humans, the genome consists of 23 pairs of chromosomes [22 autosomes (44 chromosomes and one pair of sex chromosomes (XX or XY), for a total of 46 chromosomes] located in the nucleus, as well as a small chromosome in each mitochondrion. Each human chromosome has a short arm (‘p’ for ‘petit’) and a long arm (‘q’ for ‘queue’), separated by a centromere. The ends of chromosomes are called telomeres. Each chromosome arm is divided into regions, or cytogenetic bands, that can be observed using a microscope and special stains. The cytogenetic bands are labeled p1, p2, p3, q1, q2, q3, counting from the centromere to the telomeres. At higher resolutions, sub-bands can be identified within the bands. The sub-bands are also numbered from the centromere out toward the telomere. For example, the cytogenetic map location of the MYC gene is 8q24.21, which indicates it is located on chromosome 8, q arm, band 24, sub-band 21 and sub-sub-band 2. The ends of the chromosomes are labeled ptel and qtel. For example, the notation 8qtel refers to the end of the long arm of chromosome 8 (18).

CNA represent a genetic variation class involving cumulative somatic variations. CNA are defined as non-inherited genetic alterations in somatic cells (19). These unbalanced structural variants usually contain gains or losses. Their interpretation and the CNA report continue to be a topic of interest in health and disease and have an essential role in GC (19,20). The majority of gastric adenocarcinomas, similar to numerous other types of solid tumors, exhibit defects in the maintenance of genome stability, resulting in DNA CNA that may be analyzed using comparative genomic hybridization (21) and sequencing (22). Based on the aforementioned, it is a widespread phenomenon among humans, and several studies have focused on understanding these genomic alterations that are responsible for cancer. They may be used for its diagnosis and prognosis (23).

In the present review, CNA research on samples of patients with GC is discussed. In a previous investigation, it was noted that the 8q24 cytoband exhibited alterations (24), and thus this cytoband's role in this neoplasia is reviewed below. The complete sequence of chromosome 8 has 145,138,636 bases, the NCBI RefSeq access key corresponding to the GRCh38.p14 version of the human genome is NC_000008.11, the chromosome has 34 cytobands, 2,388 genes, and 4,651 proteins. Chromosome 8 has 103 genes related to cancer; 22 of these genes are in cytoband 8q24, and seven of these genes are reported to be associated with stomach cancer (25,26) (Table I; 27–49).

Table I.

Gastric cancer-related genes.

Table I.

Gastric cancer-related genes.

GeneIDChrSummary(Refs.)
1ADGRB1a5758q24.3Angiogenesis is controlled by a local balance between stimulators and inhibitors of new vessel growth and is suppressed under normal physiologic conditions. Angiogenesis is essential for the growth and metastasis of solid tumors.(27)
2AGO2271618q24.3This gene encodes a member of the Argonaute family of proteins which play a role in RNA interference. The encoded protein is highly basic and contains a PAZ domain and a PIWI domain. It may interact with Dicer1 and play a role in short-interfering-RNA-mediated gene silencing. Multiple transcript variants encoding different isoforms have been found for this gene.(28)
3CYP11B115848q24.3This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases that catalyze numerous reactions in drug metabolism and synthesize cholesterol, steroids, and other lipids.(29,30)
4CYP11B215858q24.3This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases that catalyze numerous reactions in drug metabolism and synthesize cholesterol, steroids, and other lipids.(31)
5HSF132978q24.3The product of this gene is a transcription factor rapidly induced after temperature stress and binds heat shock promoter elements (HSE). This protein plays a role in the regulation of lifespan.(32)
6RECQL494018q24.3The protein encoded by this gene is a DNA helicase that belongs to the RecQ helicase family.(33)
7SCRIB235138q24.3The mammalian protein is involved in tumor suppression pathways. As a scaffold protein involved in cell polarization processes, this protein binds to numerous other proteins.(34)
8PTK2a57478q24.3This gene encodes a cytoplasmic protein tyrosine kinase, which is concentrated in the focal adhesions between cells growing in the presence of extracellular matrix constituents.(35)
9PTP4A3a111568q24.3This gene encodes a member of the protein-tyrosine phosphatase family. Protein tyrosine phosphatases are cell signaling molecules that play regulatory roles in various cellular processes.(36)
10PSCAa80008q24.3This gene encodes a glycosylphosphatidylinositol-anchored cell membrane glycoprotein. This gene is up- regulated in numerous prostate cancers and is also detected in bladder and pancreas cancers. This gene includes a polymorphism that results in an upstream start codon in some individuals; this polymorphism is thought to be associated with a risk for certain gastric and bladder cancers-alternative splicing results in multiple transcript variants.(37)
11EXT121318q24.11This gene encodes an endoplasmic reticulum-resident type II transmembrane glycosyltransferase involved in the chain elongation step of heparan sulfate biosynthesis.(38)
12RAD2158858q24.11This protein is a nuclear phospho-protein, which becomes hyperphosphorylated in the cell cycle M phase. The highly regulated association of this protein with mitotic chromatin, specifically at the centromere region, suggests its role in sister chromatid cohesion in mitotic cells.(39)
13CCN348568q24.12The protein encoded by this gene is a small, secreted cysteine-rich (NOV) protein and a member of the CCN family of regulatory proteins. CNN family proteins associate with the extracellular matrix and play an important role in cardiovascular and skeletal development, fibrosis, and cancer development.(40)
14TNFRSF11B49828q24.12The protein encoded by this gene is a member of the TNF-receptor superfamily.(41)
15HAS230378q24.13Hyaluronan or hyaluronic acid (HA) is a high molecular weight unbranched polysaccharide synthesized by various organisms, from bacteria to mammals, and is a constituent of the extracellular matrix. Changes in the serum concentration of HA are associated with inflammatory and degenerative arthropathies such as rheumatoid arthritis.(42)
16MTSS1a97888q24.13Predicted to be involved in the cellular response to fluid shear stress, negative regulation of epithelial cell proliferation, and urogenital system development. Predicted to act upstream of or within several processes, including actin filament polymerization; adherents junction maintenance; and magnesium ion homeostasis, which are in the actin cytoskeleton.(43)
17RNF139112368q24.13This gene was found to be interrupted by a t(3:8) translocation in a family with hereditary renal and non-medullary thyroid cancer. Studies of the Drosophila counterpart suggested that this protein may interact with tumor suppressor protein VHL and COPS5/JAB1, a protein responsible for the degradation of tumor suppressor CDKN1B/P27KIP.(44)
18CCDC261371968q24.21No data(45)
19MYCa46098q24.21This gene is a proto-oncogene and encodes a nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis, and cellular transformation.(46)
20PVT1a58208q24.21This gene represents a long non-coding RNA locus identified as a candidate oncogene. Increased copy number and overexpression of this gene are associated with numerous cancers, including breast and ovarian cancers, acute myeloid leukemia, and Hodgkin lymphoma.(47)
21CCN488408q24.22This gene encodes a WNT1 inducible signaling pathway (WISP) protein (WISP1) subfamily member, which belongs to the connective tissue growth factor (CTGF) family. It is expressed at a high level in fibroblast cells and overexpressed in colon tumors. It also attenuates p53-mediated apoptosis in response to DNA damage by activating the Akt kinase.(48)
22NDRG1103978q24.22The protein encoded by this gene is a cytoplasmic protein involved in stress responses, hormone responses, cell growth, and differentiation. The encoded protein is necessary for p53-mediated caspase activation and apoptosis.(49)

{ label (or @symbol) needed for fn[@id='tfn1-ol-27-4-14311'] } ADGRB1, adhesion G protein-coupled receptor B1; PTK2, protein tyrosine kinase 2; PTP4A3, protein tyrosine phosphatase 4A3; PSCA, prostate stem cell antigen; MTSS1, MTSS I-BAR domain containing 1; PVT1, Pvt1 oncogene; Chr, chromosome;

a , stomach cancer related-genes.

8q24 cytoband genes and single nucleotide polymorphisms (SNPs)

Alterations in the 8q24 cytoband have been associated with multiple conditions, including cancer; several mechanisms have been proposed, including chromosomal translocations (50), viral integration (51), identification of nucleotide variations (5153), and variations in the number of copies (24). The 8q24.21 cytoband is one of the most studied due to its association with various types of cancer or complex diseases; this locus has very few protein-coding genes and is rich in long non-coding RNAs (lncRNAs) (54). The latter play a range of roles in transcription and translation; however, a number of the identified variants in these regions have been insufficiently studied. The study of this locus has presented several difficulties since most of the lncRNAs in 8q24.21 are not evolutionarily conserved, and there are no mouse orthologs (55).

Currently, repositories such as ENSEMBL (56) and UCSC (57) allow the consultation of different cytobands of the human genome in their different versions. Additionally, BioMart is a tool that provides an interface for accessing database collections, which allows annotating or obtaining genomics, genetics and proteomics records, amongst other tools. With the BioMart data mining tool (58), an analysis of 8q24 (GRCh38.p13) was performed; it has a length of 138.9 megabase pairs (Mbp) and seven segments, of which q24.3 is the longest (6.2 Mbp) and the one with the most significant number of coding genes, pseudogenes and small RNAs, and q24.11 is the smallest (1.6 Mbp) (Table II).

Table II.

Description of the 8q24 cytoband. Information obtained from BioMart.

Table II.

Description of the 8q24 cytoband. Information obtained from BioMart.

Cytobands

Featuresq24.11q24.12q24.13q24.21q24.22q24.23q24.3
Start Chr116700000118300000121500000126300000130400000135400000138900000
End Chr118300000121500000126300000130400000135400000138900000145138636
Length (Mbp)1.63.24.84.15.03.56.2
Protein coding713265162103
rRNA pseudogene0100001
lncRNA411372926868
miRNA11673016
snoRNA1122202
snRNA0156021
miscRNA2223404
Processed pseudogene1715613210
Unprocessed pseudogene1000112
Transcribe processed pseudogene0011000
Polymorphic pseudogene0000001
Transcribe unitary pseudogene0000002
Transcribe unprocessed pseudogene0000002
Unitary pseudogene0000001

[i] Chr, chromosome; lncRNA, long non-coding RNA; miRNA, microRNA; snoRNA, small nucleolar RNA; snRNA, small nuclear RNA; miscRNA, miscellaneous RNA.

The 8q24 cytoband has 509 genes: 172 coding genes and 337 non-coding genes; among the non-coding ones, lncRNAs, microRNAs, miscellaneous RNAs, small nucleolar RNAs, small nuclear RNAs, and processed, unprocessed, polymorphic pseudogenes were identified (Table SI).

The most studied genes of this cytoband are those belonging to the MYC family (8q24.21: c-MYC, l-MYC, and n-MYC). The c-MYC proto-oncogene is affected in almost 20% of the different types of cancer, and it is suspected that it may be related to the functioning of other genes (59). It is a coding gene that participates in cell division and multiplication, maturation and apoptosis. To date, when searching for information on ‘8q24 cytoband AND cancer’ in PubMed (https://www.ncbi.nlm.nih.gov/pmc/), 248 articles were found (April 2023). When exploring the combination ‘8q24 cytoband AND GC’, 73 articles were found; however, when performing an advanced search (selecting the ‘Title and Abstract’ options) in PubMed with the combination ‘8q24 AND cancer’ a total of 1,553 articles were found, whereas when using ‘8q24 AND GC’ as the search term, only 50 articles were returned (Table SII). Based on these analyses, Fig. 2 was constructed, which serves as an axis for the following parts of the present review.

A total of three genes (pink rectangles) are demonstrated in Fig. 2: MYC, PVT1 and PTK2, which have been reported to be altered in GC (Table I), and nine genes (yellow rectangles) in which SNP alterations in GC have been described; the cytobands in which they were located were 8q24.13, 8q24.21 and 8q24.3. The information on all these cytobands can be found in Table SIII.

A total of seven genes related to GC are in cytoband 8q24 (ADGRB1, MTSS1, MYC, PSCA, PTK2, PTP4A3, and PVT1; Table I). The present bibliographic analysis determined the most frequently cited 12 genes (NSMCE2, PCAT1, CASC19, CASC8, CCAT2, PRNCR1, POU5F1B, PSCA, JRK, MYC, PVT1 and PTK2) (Table SIII). The genes that were present in both search strategies were MYC, PVT1, PTK2 and PSCA, and of these, the PSCA gene was the most cited in GC articles.

The PSCA gene has four SNPs: i) rs2978980, which is located at a functional enhancer in the 8q24.3 GC-susceptibility locus (60,61); ii) rs2294008, the T allele of which is a risk allele for diffuse-type GC (62); iii) rs2976392, which is associated with alterations in apoptosis/proliferation (63); iv) rs9297976, which can potentially be recommended as a criterion for identifying high-risk groups for the development of GC (64).

SNPs and the risk of cancer

A SNP is a genomic variant at a single base position in DNA. Numerous studies have focused on identifying the mechanisms of specific SNPs in a genome on health, disease, drug responses, and other traits in SNPs can occur in promoters, exons, introns, untranslated regions (UTRs), amongst other regions; the molecular mechanisms that may be affected are described in Table III.

Table III.

Molecular mechanisms of region-based SNP on cancer susceptibility.

Table III.

Molecular mechanisms of region-based SNP on cancer susceptibility.

SNP regionsPossible molecular mechanismUnclear issues
PromoterGenetic regulation: promoter activity (TATA box, transcription-factor binding ability)The interaction between genetic and epigenetic elements
Epigenetic regulation: DNA methylation, histone modificationEffect of SNPs on DNA methylation status
ExonsNon-synonymous cSNPs: coding protein structure and functionDetail mechanism at the biochemical and cellular level
Synonymous cSNPs: secondary structure conformation translation dynamicsMechanism of the kinetics of translation
Intronscis-regulatory elements mRNA splicing genomic imprinting long non-coding RNAs chromatin loopingDetail functions of cis-regulatory elements and splicing
UTRs5′-UTRs: protein translation and transcription activityHow SNPs in the 5′-UTR affect the efficiency of translation
3′-UTRs: Regulate mRNA degradation and translationHow does the 3′-UTR affect miRNA binding sites
Non-definite regionsLong-range cis-regulation tRNA and rRNAThe ways polymorphisms affect long-range cis-regulation, tRNA and rRNA

[i] Taken from (65); SNP, single nucleotide polymorphism; UTR, untranslated region.

These alterations, as shown, affect the control of transcription and/or translation of the genes. These sequence changes can be insignificant or very relevant, affecting key molecules or ‘checkpoints’ of cellular homeostasis and leading to a predisposition to specific diseases such as various types of cancer, particularly in GC.

In the present review, 12 genes present in cytoband 8q24 related to GC (NSMCE2, PCAT1, CASC19, CASC8, CCAT2, PRNCR1, POU5F1B, PSCA, JRK, MYC, PVT1 and PTK2) are discussed. The PSCA gene was cited more frequently than others; it has four known SNPs associated with GC (rs2978980, rs2294008, rs2976392 and rs9297976). Thus, these SNPs should be further studied in different populations to determine their risk value in patients with GC.

Conclusions

Alterations in cytoband 8q24 can occur at the structural level (deletions, insertions and translocations, among other types), at the functional level (genes and proteins), and at the SNP level, which can translate to a risk of suffering from a disease depending on the base that is mutated, that is, if it occurs in an oncogene or tumor suppressor gene and the function of the affected gene. In GC, mutations in the PSCA gene and the presence of SNPs are consistent and are thus deserved of further study.

Supplementary Material

Supporting Data
Supporting Data
Supporting Data

Acknowledgements

The authors would like to thank Ms. Alejandra García Bejarano and Ms. Araceli Peralta Aguilar (Medical Research Unit in Oncological Diseases, Oncology Hospital, Century XXI National Medical Center, Mexican Social Security Institute) for support in bibliographic organization, and Dr Penélope Aguilera [Cerebral Vascular Pathology Laboratory, National Institute of Neurology and Neurosurgery (INNN)] for the English editing and critical revision of the manuscript.

Funding

Funding: No funding was received.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

VLS and HAVS, participated in the analysis of results, preparation, writing, and discussion of the manuscript. MERT was responsible for the design of the present study. VLS, HAVS and MERT supervised, critically reviewed, edited and wrote the manuscript. Data authentication is not applicable. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Slominski RM, Raman C, Chen JY and Slominski AT: How cancer hijacks the body's homeostasis through the neuroendocrine system. Trends Neurosci. 46:263–275. 2023. View Article : Google Scholar : PubMed/NCBI

2 

Global Cancer Observatory: 900 World Fact Sheet. https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdfFebruary 22–2024

3 

Li J: Digestive cancer incidence and mortality among young adults worldwide in 2020: A population-based study. World J Gastrointest Oncol. 14:278–294. 2022. View Article : Google Scholar : PubMed/NCBI

4 

McLean MH and El-Omar EM: Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol. 11:664–674. 2014. View Article : Google Scholar : PubMed/NCBI

5 

Nagini S: Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics, and chemoprevention. World J Gastrointest Oncol. 4:156–169. 2012. View Article : Google Scholar : PubMed/NCBI

6 

Choi YJ and Kim N: Gastric cancer and family history. Korean J Intern Med. 31:1042–1053. 2016. View Article : Google Scholar : PubMed/NCBI

7 

Ansari S, Gantuya B, Tuan VP and Yamaoka Y: Diffuse astric cancer: A summary of analogous contributing factors for its molecular pathogenicity. Int J Mol Sci. 19:24242018. View Article : Google Scholar : PubMed/NCBI

8 

Ming SC: Gastric carcinoma. A pathobiological classification. Cancer. 39:2475–2485. 1977. View Article : Google Scholar : PubMed/NCBI

9 

Correa P: Human gastric carcinogenesis: A multistep and multifactorial process-first american cancer society award lecture on cancer epidemiology and Prevention. Cancer Res. 52:6735–6740. 1992.PubMed/NCBI

10 

Karimi P, Islami F, Anandasabapathy S, Freedman ND and Kamangar F: Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 23:700–713. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 64:31–49. 1965. View Article : Google Scholar : PubMed/NCBI

12 

Nakamura K, Sugano H and Takagi K: Carcinoma of the stomach in incipient phase: Its histogenesis and histological appearances. Gan. 59:251–258. 1968.PubMed/NCBI

13 

Goseki N, Takizawa T and Koike M: Differences in the mode of the extension of gastric cancer classified by histological type: New histological classification of gastric carcinoma. Gut. 33:606–612. 1992. View Article : Google Scholar : PubMed/NCBI

14 

Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA; WHO Classification of Tumours Editorial Board, : The 2019 WHO classification of tumours of the digestive system. Histopathology. 76:182–188. 2020. View Article : Google Scholar : PubMed/NCBI

15 

Hartgrink HH, Jansen EPM, van Grieken NC and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009. View Article : Google Scholar : PubMed/NCBI

16 

Jang BG and Kim WH: Molecular pathology of gastric carcinoma. Pathobiology. 78:302–310. 2011. View Article : Google Scholar : PubMed/NCBI

17 

Suárez-Arriaga MC, Ribas-Aparicio RM and Ruiz-Tachiquín ME: MicroRNAs in hereditary diffuse gastric cancer. Biomed Rep. 5:151–154. 2016. View Article : Google Scholar : PubMed/NCBI

18 

An International System for Human Cytogenetic Nomenclature, . Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature, Memphis, Tennessee, USA. Karger Medical and Scientific Publishers; 1995

19 

Wallander K, Eisfeldt J, Lindblad M, Nilsson D, Billiau K, Foroughi H, Nordenskjöld M, Liedén A and Tham E: Cell-free tumour DNA analysis detects copy number alterations in gastro-oesophageal cancer patients. PLoS One. 16:e02454882021. View Article : Google Scholar : PubMed/NCBI

20 

Han B, Ren D, Mao B, Song X, Yang W, Zhang H and Gao F: Tumor copy number alteration (CNA) burden as a prognostic factor for overall survival in Chinese gastric cancers. J Clin Oncol. 37 (Suppl 15):e155552019.(In Chinese). View Article : Google Scholar

21 

Milne AN and Offerhaus GJ: Early-onset gastric cancer: Learning lessons from the young. World J Gastrointest Oncol. 2:59–64. 2010. View Article : Google Scholar : PubMed/NCBI

22 

Gordeeva V, Sharova E, Babalyan K, Sultanov R, Govorun VM and Arapidi G: Benchmarking germline CNV calling tools from exome sequencing data. Sci Rep. 11:144162021. View Article : Google Scholar : PubMed/NCBI

23 

Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW and Lee C: Detection of large-scale variation in the human genome. Nat Genet. 36:949–951. 2004. View Article : Google Scholar : PubMed/NCBI

24 

Larios-Serrato V, Martínez-Ezquerro JD, Valdez-Salazar HA, Torres J, Camorlinga-Ponce M, Piña-Sánchez P and Ruiz-Tachiquín ME: Copy number alterations and epithelial-mesenchymal transition genes in diffuse and intestinal gastric cancers in Mexican patients. Mol Med Rep. 25:1912022. View Article : Google Scholar : PubMed/NCBI

25 

Cancer Genetic Web, . Genes Linked with Cancer in Chromosome 8. https://www.cancer-genetics.org/clinkc08.htmApril 30–2023

26 

Logsdon GA, Vollger MR, Hsieh P, Mao Y, Liskovykh MA, Koren S, Nurk S, Mercuri L, Dishuck PC, Rhie A, et al: The structure, function and evolution of a complete human chromosome 8. Nature. 593:101–107. 2021. View Article : Google Scholar : PubMed/NCBI

27 

ADGRB1 adhesion G protein-coupled receptor B1 [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=575April 30–2023

28 

AGO2 argonaute RISC catalytic component 2 [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene/27161April 30–2023

29 

CYP11B1 cytochrome P450 family 11 subfamily B member 1 [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=1584April 30–2023

30 

Slominski RM, Tuckey RC, Manna PR, Jetten AM, Postlethwaite A, Raman C and Slominski AT: Extra-adrenal glucocorticoid biosynthesis: Implications for autoimmune and inflammatory disorders. Genes Immun. 21:150–168. 2020. View Article : Google Scholar : PubMed/NCBI

31 

CYP11B2 cytochrome P450 family 11 subfamily B member 2 [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=1585April 30–2023

32 

HSF1 heat shock transcription factor 1 [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=3297April 30–2023

33 

RECQL4 RecQ like helicase 4 [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=5965April 30–2023

34 

SCRIB scribble planar cell polarity protein [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=23513April 30–2023

35 

PTK2 protein tyrosine kinase 2 [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=5747April 30–2023

36 

PTP4A3 protein tyrosine phosphatase 4A3 [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=11156April 30–2023

37 

PSCA prostate stem cell antigen [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=8000April 30–2023

38 

EXT1 exostosin glycosyltransferase 1 [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=2131April 30–2023

39 

RAD21 RAD21 cohesin complex component [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=5885April 30–2023

40 

CCN3 cellular communication network factor 3 [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=4856April 30–2023

41 

TNFRSF11B TNF receptor superfamily member 11b [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=4982April 30–2023

42 

HAS2 hyaluronan synthase 2 [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=3037April 30–2023

43 

MTSS1 MTSS I-BAR domain containing 1 [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=9788April 30–2023

44 

RNF139 ring finger protein 139 [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=11236April 30–2023April 30–2023

45 

CCDC26 CCDC26 long non-coding RNA [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=137196April 30–2023

46 

MYC MYC proto-oncogene, bHLH transcription factor [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=4609April 30–2023

47 

PVT1 Pvt1 oncogene [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=5820April 30–2023

48 

CCN4 cellular communication network factor 4 [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=8840April 30–2023

49 

NDRG1 N-myc downstream regulated 1 [Homo sapiens (human)]-Gene-NCBI, . https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=10397April 30–2023

50 

Zech L, Haglund U, Nilsson K and Klein G: Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer. 17:47–56. 1976. View Article : Google Scholar : PubMed/NCBI

51 

zur Hausen A, Brink AA, Craanen ME, Middeldorp JM, Meijer CJ and van den Brule AJ: Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: Expression of the transforming BARF1 gene. Cancer Res. 60:2745–2748. 2000.PubMed/NCBI

52 

Gómez-Carpintero García A, Vidal Esteban A, Bermejo Gómez A and Púa Torrejón RC: Phenotype and variations associated with the deletion of the 1q44 cytoband and the pathogenic duplication in the 9q32q34.3 cytobands. BMJ Case Rep. 13:e2319382020. View Article : Google Scholar : PubMed/NCBI

53 

Brisbin AG, Asmann YW, Song H, Tsai YY, Aakre JA, Yang P, Jenkins RB, Pharoah P, Schumacher F, Conti DV, et al: Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development. BMC Med Genet. 12:1562011. View Article : Google Scholar : PubMed/NCBI

54 

Wilson C and Kanhere A: 8q24.21 locus: A paradigm to link non-coding RNAs, genome polymorphisms and cancer. Int J Mol Sci. 22:10942021. View Article : Google Scholar : PubMed/NCBI

55 

Sun Y and Ma L: New insights into long non-coding RNA MALATI in cancer and metastasis. Cancers (Basel). 11:2162019. View Article : Google Scholar : PubMed/NCBI

56 

Cunningham F, Allen JE, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, Austine-Orimoloye O, Azov AG, Barnes I, Bennett R, et al: Ensembl 2022. Nucleic Acids Res. 50((D1)): D988–D995. 2022. View Article : Google Scholar : PubMed/NCBI

57 

Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM and Haussler D: The human genome browser at UCSC. Genome Res. 12:996–1006. 2002. View Article : Google Scholar : PubMed/NCBI

58 

Smedley D, Haider S, Ballester B, Holland R, London D, Thorisson G and Kasprzyk A: BioMart-biological queries made easy. BMC Genomics. 10:222009. View Article : Google Scholar : PubMed/NCBI

59 

Prochownik EV: Regulation of normal and neoplastic proliferation and metabolism by the extended Myc network. Cells. 11:39742022. View Article : Google Scholar : PubMed/NCBI

60 

Zheng Y, Lei T, Jin G, Guo H, Zhang N, Chai J, Xie M, Xu Y, Wang T, Liu J, et al: LncPSCA in the 8q24.3 risk locus drives gastric cancer through destabilizing DDX5. EMBO Rep. 22:e527072021. View Article : Google Scholar : PubMed/NCBI

61 

Yang W, Zhang T, Song X, Dong G, Xu L and Jiang F: SNP-target genes interaction perturbing the cancer risk in the post-GWAS. Cancers (Basel). 14:56362022. View Article : Google Scholar : PubMed/NCBI

62 

Iwasaki RL, Ishiya K, Kanzawa-Kiriyama H, Kawai Y, Gojobori J and Satta Y: Evolutionary history of the risk of SNPs for diffuse-type gastric cancer in the Japanese population. Genes (Basel). 11:7752020. View Article : Google Scholar : PubMed/NCBI

63 

Duan F, Song C, Shi J, Wang P, Ye H, Dai L, Zhang J and Wang K: Identification and epidemiological evaluation of gastric cancer risk factors: Based on a field synopsis and meta-analysis in Chinese population. Aging (Albany NY). 13:21451–21469. 2021. View Article : Google Scholar : PubMed/NCBI

64 

Turdikulova S, Dalimova D, Abdurakhimov A, Adilov B, Navruzov S, Yusupbekov A, Djuraev M, Abdujapparov S, Egamberdiev D and Mukhamedov R: Association of rs2294008 and rs9297976 polymorphisms in PSCA gene with gastric cancer Ssusceptibility in uzbekistan. Cent Asian J Glob Health. 5:2272016.PubMed/NCBI

65 

Deng N, Zhou H, Fan H and Yuan Y: Single nucleotide polymorphisms and cancer susceptibility. Oncotarget. 8:110635–110649. 2017. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April-2024
Volume 27 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Larios-Serrato V, Valdez-Salazar H and Ruiz-Tachiquín M: The landscape of 8q24 cytoband in gastric cancer (Review). Oncol Lett 27: 179, 2024
APA
Larios-Serrato, V., Valdez-Salazar, H., & Ruiz-Tachiquín, M. (2024). The landscape of 8q24 cytoband in gastric cancer (Review). Oncology Letters, 27, 179. https://doi.org/10.3892/ol.2024.14311
MLA
Larios-Serrato, V., Valdez-Salazar, H., Ruiz-Tachiquín, M."The landscape of 8q24 cytoband in gastric cancer (Review)". Oncology Letters 27.4 (2024): 179.
Chicago
Larios-Serrato, V., Valdez-Salazar, H., Ruiz-Tachiquín, M."The landscape of 8q24 cytoband in gastric cancer (Review)". Oncology Letters 27, no. 4 (2024): 179. https://doi.org/10.3892/ol.2024.14311